AU4068599A - Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction - Google Patents
Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunctionInfo
- Publication number
- AU4068599A AU4068599A AU40685/99A AU4068599A AU4068599A AU 4068599 A AU4068599 A AU 4068599A AU 40685/99 A AU40685/99 A AU 40685/99A AU 4068599 A AU4068599 A AU 4068599A AU 4068599 A AU4068599 A AU 4068599A
- Authority
- AU
- Australia
- Prior art keywords
- phentolamine
- treatment
- combination
- sexual dysfunction
- phosphodiesterase inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8164098A | 1998-05-20 | 1998-05-20 | |
US09081640 | 1998-05-20 | ||
US8297798A | 1998-05-21 | 1998-05-21 | |
US09082977 | 1998-05-21 | ||
US10651798A | 1998-06-29 | 1998-06-29 | |
US09106517 | 1998-06-29 | ||
PCT/US1999/007046 WO1999059584A1 (en) | 1998-05-20 | 1999-05-17 | Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction |
Publications (1)
Publication Number | Publication Date |
---|---|
AU4068599A true AU4068599A (en) | 1999-12-06 |
Family
ID=27374039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU40685/99A Abandoned AU4068599A (en) | 1998-05-20 | 1999-05-17 | Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU4068599A (en) |
PE (1) | PE20000547A1 (en) |
WO (1) | WO1999059584A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU769946B2 (en) * | 1999-04-30 | 2004-02-12 | Icos Corporation | Unit dosage form |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2362918A1 (en) * | 1999-03-08 | 2000-09-14 | Elizabeth Stoner | Methods and compositions for treating erectile dysfunction |
US6943166B1 (en) | 1999-04-30 | 2005-09-13 | Lilly Icos Llc. | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
TWI265925B (en) | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
BRPI0003386B8 (en) | 2000-08-08 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | homo- or heterodimeric prodrugs useful in treating diseases or disorders mediated by phosphodiesterases; pharmaceutical compositions containing the prodrug or its pharmaceutical acceptable salts; process of obtaining these prodrugs |
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
US8227476B2 (en) | 2005-08-03 | 2012-07-24 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
US7923449B2 (en) | 2005-10-29 | 2011-04-12 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
ES2336719T3 (en) | 2006-06-30 | 2010-04-15 | Boehringer Ingelheim International Gmbh | FLIBANSERINE FOR THE TREATMENT OF URINARY INCONTINENCE AND RELATED DISEASES. |
CA2660476C (en) | 2006-08-14 | 2015-11-17 | Boehringer Ingelheim International Gmbh | Formulations of flibanserin and method for manufacturing the same |
CA2661613C (en) | 2006-08-25 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Controlled release system and method for manufacturing the same |
UY31335A1 (en) | 2007-09-12 | 2009-04-30 | VASOMOTOR SYMPTOMS TREATMENT |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0611248B1 (en) * | 1993-02-10 | 2000-03-22 | B.M.R.A. Corporation B.V. | Pharmaceutical composition for treating impotence containing an alpha-1-inhibitor and an alpha-2 inhibitor |
GB9301192D0 (en) * | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
US5731339A (en) * | 1995-04-28 | 1998-03-24 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
GB9514464D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
-
1999
- 1999-05-17 WO PCT/US1999/007046 patent/WO1999059584A1/en active Application Filing
- 1999-05-17 AU AU40685/99A patent/AU4068599A/en not_active Abandoned
- 1999-05-18 PE PE1999000419A patent/PE20000547A1/en not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU769946B2 (en) * | 1999-04-30 | 2004-02-12 | Icos Corporation | Unit dosage form |
AU769946C (en) * | 1999-04-30 | 2005-01-13 | Icos Corporation | Unit dosage form |
Also Published As
Publication number | Publication date |
---|---|
WO1999059584A1 (en) | 1999-11-25 |
PE20000547A1 (en) | 2000-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL138907A0 (en) | Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction | |
EP1027054A4 (en) | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | |
AU5785699A (en) | Combinations of tetracyclic cyclic gmp-specific phosphodiesterase inhibitors with further therapeutic agents | |
GB9608408D0 (en) | Treatment of erectile dysfunction | |
AU4583899A (en) | Nasal administration of sildenafil for the treatment of erectile dysfunction | |
EP1143987A4 (en) | Natural composition and method for the treatment of sexual dysfunction | |
IL155589A0 (en) | Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders | |
AU4068599A (en) | Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction | |
AP2000001796A0 (en) | The use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function | |
AU2001250821A1 (en) | Methods and compositions for the treatment and prevention of erectile dysfunction | |
HUP0200912A3 (en) | Compositions comprising phosphodiesterase inhibitors for the treatment of sexual disfunction | |
EP1117395A4 (en) | Compounds for the treatment of estrogen-dependent illnesses and methods for making and using the same | |
AU3894600A (en) | Method of treating sexual dysfunction | |
PL361733A1 (en) | Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors | |
AU6562100A (en) | Method for the anticorrosive treatment or post-treatment of metal surfaces | |
AU4676099A (en) | Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction | |
AU7652400A (en) | Novel combination for the treatment of sexual dysfunction | |
AU2002246924A1 (en) | Treatment of erectile dysfunction with rho-kinase inhibitors | |
AU8906201A (en) | Methods and compositions for the treatment and prevention of sexual dysfunction | |
AU1646201A (en) | Pharmaceutical agent for the treatment of cachexia and/or cardiogenic shock | |
AU2566201A (en) | Compounds and methods for the treatment of pain | |
IL137439A0 (en) | Method for the determination of prosthetic infections | |
AU2420101A (en) | Method and composition for the treatment of pain | |
IL128816A (en) | Process for the preparation of chloroalkynes and alkynyl amines | |
IL150208A0 (en) | Compound and method for the treatment of pain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |